Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor

por Jang, Seong, Strickland, Bill, Finis, Lynda, Kooijman, Jeffrey J., Melis, Janneke J. T. M., Zaman, Guido J. R., Van Tornout, Jan
Publicado 2023

LBODP106 Multi-omics Analyses Of MEN1 Missense Mutations Identify Disruption Of Menin-MLL And Menin-JunD Interactions As Critical Requirements For Molecular Pathogenicity

por Dreijerink, Koen Marie Anton, Ozyerli-Goknar, Ezgi, Koidl, Stefanie, Van der Lelij, Ewoud, Van den Heuvel, Priscilla, Kooijman, Jeffrey, Biniossek, Martin, Rodenburg, Kees, Nizamuddin, Sheikh, Timmers, Marc
Publicado 2022

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors

por Conlon, Neil T., Kooijman, Jeffrey J., van Gerwen, Suzanne J. C., Mulder, Winfried R., Zaman, Guido J. R., Diala, Irmina, Eli, Lisa D., Lalani, Alshad S., Crown, John, Collins, Denis M.
Publicado 2021

Multi-omics analyses of MEN1 missense mutations identify disruption of menin–MLL and menin–JunD interactions as critical requirements for molecular pathogenicity

por Dreijerink, Koen M. A., Ozyerli-Goknar, Ezgi, Koidl, Stefanie, van der Lelij, Ewoud J., van den Heuvel, Priscilla, Kooijman, Jeffrey J., Biniossek, Martin L., Rodenburg, Kees W., Nizamuddin, Sheikh, Timmers, H. T. Marc
Publicado 2022

Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020

por Kooijman, Jeffrey J., van Riel, Wilhelmina E., Dylus, Jelle, Prinsen, Martine B. W., Grobben, Yvonne, de Bitter, Tessa J. J., van Doornmalen, Antoon M., Melis, Janneke J. T. M., Uitdehaag, Joost C. M., Narumi, Yugo, Kawase, Yusuke, de Roos, Jeroen A. D. M., Willemsen-Seegers, Nicole, Zaman, Guido J. R.
Publicado 2022